
Ophthalmologist

No OPD information available
Orbital Cellulitis
Retinoblastoma
Gliomatosis Cerebri
Periorbital Cellulitis
Phillipa Sharwood is a female medical professional who helps patients with eye and brain conditions like orbital cellulitis, retinoblastoma, gliomatosis cerebri, and periorbital cellulitis.
She uses her special skills and treatments to care for patients with these conditions. She is known for her expertise in treating eye and brain problems.
Phillipa Sharwood communicates with patients in a kind and caring way, which helps patients feel comfortable and trust her. Patients appreciate her clear explanations and the way she listens to their concerns.
To stay updated with the latest medical knowledge and research, Phillipa Sharwood regularly attends conferences, reads medical journals, and collaborates with other experts in the field. This helps her provide the best care possible for her patients.
Phillipa Sharwood works well with her colleagues and values teamwork in treating patients. She shares knowledge and collaborates with other medical professionals to ensure the best outcomes for her patients.
Through her work, Phillipa Sharwood has positively impacted many patients' lives by providing effective treatments and improving their health. Her dedication to her patients' well-being is evident in the positive outcomes she achieves.
One of her notable publications is "Stenotrophomonas maltophilia: A Rare Cause of Pediatric Endogenous Endophthalmitis" in the Journal of Pediatrics and Child Health. This publication showcases her expertise in treating rare eye conditions.
She is also involved in a clinical trial called "Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial," which aims to improve treatment for children with eye inflammation.
Overall, Phillipa Sharwood is a dedicated and skilled medical professional who makes a difference in the lives of her patients through her expertise, compassionate care, and commitment to staying updated with the latest advancements in her field.
Enrollment Status: Active not recruiting
Published: March 26, 2025
Intervention Type: Other, Biological
Study Drug: Adalimumab
Study Phase: Phase 4
